In this study, western blotting and triple immunofluorescence staining results showed that CB treatment activated the NLRP3 inflammasome in HCC cells, as evidenced by elevated levels of NLRP3, ASC, cleaved caspase-1, cleaved IL-1β, and cleaved IL-18. The gene discussed is NLRP3; the disease is hepatocellular carcinoma.